Interstitial cystitis (IC) drugs market size to increase by USD 369.58 million: Analysis of major players as well as the key contributor region - Technavio

2023-01-31
PRNewswire
North America will account for 35% of the global interstitial cystitis (IC) drugs market
NEW YORK, Jan. 30, 2023 /PRNewswire/ -- North America will account for 35% of the global Interstitial cystitis (IC) drugs market growth. The increasing cases of interstitial cystitis and the rise in research funding are driving the growth of the regional market. The
Interstitial Cystitis Drugs Market by Type, Distribution Channel, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 5.9% and register an incremental growth of
USD 369.58 million during the forecast period. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market.
Download a PDF Sample Report
Continue Reading
Technavio has announced its latest market research report titled Global Interstitial Cystitis Drugs Market
Company ProfilesInterstitial Cystitis
The interstitial cystitis (IC) drugs market report includes information on the key products and recent developments of leading vendors, including:
Amneinterstitial cystitisc: The company offers interstitial cystitis and other related drugs such as Pyridium.
Amneal Pharmaceuticals Incompany offers interstinterstitial cystitissuch as Rosiptor.Pyridium
Astellas Pharma Incny offers interstitiainterstitial cystitis as Aleve and ARosiptor
Bayer AGy and Co: The companyinterstitial cystitiscystitis and otAleveelated drugs such as Tadalafil.
JohnLilly and Coson: The company offeinterstitial cystitistis drugs such as Elmiron.Tadalafil
Seikagaku Corp.to more vendor profiles available with Technavio,
buy the report!
Market Dynamics
The market is driven by factors such as the high prevalence of interstitial cystitis, increasing awareness of interstitial cystitis, and increasing grants for research on interstitial cystitis. However, the lack of approved drugs is hindering the market growth.
The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others.
Request a Sample
Market Segmentation
By type, the market is segmented into
oral therapy and intravesical therapy. The
oral therapy segment accounted for the largest share of the market.
By geography, the market is segmented into
North America, Europe, Asia, and Rest of World (ROW).
North America held the largest share of the market.
Related Reports:
Chronic Obstructive Pulmonary Disease Drugs Market by Product, Distribution Channel and Geography - Forecast and Analysis 2023-2027: The chronic obstructive pulmonary disease drugs market is estimated to grow at a
USD 6,654.49 million. The rising prevalence of COPD is notably driving the market growth, although factors such as the high cost of conducting clinical trials in COPD may impede the market growth.
Allergy Immunotherapies Market by Product, TypeCOPDd Geography - Forecast and Analysis 2023-2027: The allergy immunotherapies market is estimated to grow at aCOPD
Allergy 8.95% between 2022 and 2027. The size of the market is forecast to increase byallergy
USD 1,010.37 million. The increasing prevalence of allergies is notably driving the market growth, although factors such as trial failures may impede the market growth.
Technavio's library includes over 17,000+ reports, allergiesmore than 2,000 emerging technologies.
Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights
What are the key data covered in this interstitial cystitis (IC) drugs market report?
CAGR of the market during the forecastinterstitial cystitis (IC)
Detailed information on factors that will drive the growth of interstitial cystitis (IC) drugs market between 2023 and 2027
Precise estimation of the size of interstitial cystitis (IC) dinterstitial cystitis (IC)bution to the parent market
Accurate predictions about upcomininterstitial cystitisin consumer behavior
Growth of interstitial cystitis (IC) drugs market across North America, Europe, Asia, and Rest of World (ROW)
A thoroughinterstitial cystitis (IC)competitive landscape and detailed information about vendors
Comprehensive analysis of factors that will challenge the growth of interstitial cystitis (IC) drugs market vendors
Browse for Technavio "Health Care" Research Reportsinterstitial cystitis (IC)
Table of Content
1 Executive Summary
2 Market Landscape
2.1 Market ecosystem
Exhibit 01: Parent market
Exhibit 02: Market characteristics
2.2 Value chain analysis
Exhibit 03: Value chain analysis: Pharmaceuticals
3 Market Sizing
3.1 Market definition
Exhibit 04: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 05: Market segments
3.3 Market size 2020
3.4 Market outlook: Forecast for 2020 - 2025
Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)
4 Five Forces Analysis
4.1 Five forces summary
Exhibit 08: Five forces analysis 2020 & 2025
4.2 Bargaining power of buyers
Exhibit 09: Bargaining power of buyers
4.3 Bargaining power of suppliers
Exhibit 10: Bargaining power of suppliers
4.4 Threat of new entrants
Exhibit 11: Threat of new entrants
4.5 Threat of substitutes
Exhibit 12: Threat of substitutes
4.6 Threat of rivalry
Exhibit 13: Threat of rivalry
4.7 Market condition
Exhibit 14: Market condition - Five forces 2020
5 Market Segmentation by Type
5.1 Market segments
Exhibit 15: Type - Market share 2020-2025 (%)
5.2 Comparison by Type
Exhibit 16: Comparison by Type
5.3 Oral therapy - Market size and forecast 2020-2025
Exhibit 17: Oral therapy - Market size and forecast 2020-2025 ($ million)
Exhibit 18: Oral therapy - Year-over-year growth 2020-2025 (%)
5.4 Intravesical therapy - Market size and forecast 2020-2025
Exhibit 19: Intravesical therapy - Market size and forecast 2020-2025 ($ million)
Exhibit 20: Intravesical therapy - Year-over-year growth 2020-2025 (%)
5.5 Market opportunity by Type
Exhibit 21: Market opportunity by Type
6 Customer landscape
7 Geographic Landscape
7.1 Geographic segmentation
Exhibit 23: Market share by geography 2020-2025 (%)
7.2 Geographic comparison
Exhibit 24: Geographic comparison
7.3 North America - Market size and forecast 2020-2025
Exhibit 25: North America - Market size and forecast 2020-2025 ($ million)
Exhibit 26: North America - Year-over-year growth 2020-2025 (%)
7.4 Europe - Market size and forecast 2020-2025
Exhibit 27: Europe - Market size and forecast 2020-2025 ($ million)
Exhibit 28: Europe - Year-over-year growth 2020-2025 (%)
7.5 Asia - Market size and forecast 2020-2025
Exhibit 29: Asia - Market size and forecast 2020-2025 ($ million)
Exhibit 30: Asia - Year-over-year growth 2020-2025 (%)
7.6 ROW - Market size and forecast 2020-2025
Exhibit 31: ROW - Market size and forecast 2020-2025 ($ million)
Exhibit 32: ROW - Year-over-year growth 2020-2025 (%)
7.7 Key leading countries
Exhibit 33: Key leading countries
7.8 Market opportunity by geography
Exhibit 34: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
Exhibit 35: Impact of drivers and challenges
8.3 Market trends
9 Vendor Landscape
9.1 Overview
9.2 Vendor landscape
Exhibit 36: Vendor landscape
9.3 Landscape disruption
Exhibit 37: Landscape disruption
Exhibit 38: Industry risks
10 Vendor Analysis
10.1 Vendors covered
Exhibit 39: Vendors covered
10.2 Market positioning of vendors
Exhibit 40: Market positioning of vendors
10.3 Astellas Pharma Inc.
ExhibAstellas Pharma Inc.ma Inc. - Overview
Exhibit 42: Astellas Pharma Inc. - Product and service
Exhibit 43: Astellas Pharma Inc. - Key news
Exhibit 44: Astellas Pharma Inc. - Key offerings
ExhibBayer AGayer AG - Overview
Exhibit 46: Bayer AG - Business segments
Exhibit 47: Bayer AG - Key news
Exhibit 48: Bayer AG - Key offerings
Exhibit 49: Bayer AG - Segment focus
10.5 JohnsonBayer AGnson Inc.
Exhibit 50: Johnson and Johnson Inc. - Overview
Exhibit 51: Johnson and Johnson Inc. - Business segments
Exhibit 52: Johnson and Johnson Inc. - Key news
Exhibit 53: Johnson and Johnson Inc. - Key offerings
Exhibit 54: Johnson and Johnson Inc. - Segment focus
10.6 Novartis AG
ExhibNovartis AGrtis AG - Overview
Exhibit 56: Novartis AG - Business segments
Exhibit 57: Novartis AG - Key news
Exhibit 58: Novartis AG - Key offerings
Exhibit 59: Novartis AG - Segment focus
10.7 PerrigoNovartis AG
ExhibPerrigo Co. PlcCo. Plc - Overview
Exhibit 61: Perrigo Co. Plc - Business segments
Exhibit 62: Perrigo Co. Plc - Key news
Exhibit 63: Perrigo Co. Plc - Key offerings
Exhibit 64: Perrigo Co. Plc - Segment focus
10.8 Pfizer Perrigo Co.
10.9 Pfizer Inc.orp.
ExhibSeikagaku Corp.u Corp. - Overview
Exhibit 70: Seikagaku Corp. - Business segments
Exhibit 71: Seikagaku Corp. - Key offerings
Exhibit 72: Seikagaku Corp. - Segment focus
10.10 Sun PhSeikagaku Corp.dustries Ltd.
ExhibiSun Pharmaceutical Industries Ltd.s Ltd. - Overview
Exhibit 74: Sun Pharmaceutical Industries Ltd. - Product and service
Exhibit 75: Sun Pharmaceutical Industries Ltd. - Key news
Exhibit 76: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 78: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 79: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 80: Teva Pharmaceutical Industries Ltd. - Segment focus
ExhibiViatris Inc.s Inc. - Overview
Exhibit 82: Viatris Inc. - Business segments
Exhibit 83: Viatris Inc. - Key offerings
Exhibit 84: Viatris Inc. - Segment focus
11 AppendixViatris Inc.
11.1 Scope of the report
11.2 Currency conversion rates for US$
Exhibit 85: Currency conversion rates for US$
11.3 Research methodology
Exhibit 86: Research Methodology
Exhibit 87: Validation techniques employed for market sizing
Exhibit 88: Information sources
11.4 List of abbreviations
Exhibit 89: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。